Home >Current Issue
Volume: 9, Issue: 8, August, 2019
Development and evaluation of liquid oral controlled release systems for Losartan potassiumAuthor Affiliations
Losartan potassium is a water soluble antihypertensive agent with short half-life. Controlling its release will improve patient compliance. The benefit will be extended for geriatric patients if the developed system was liquid. The objective of this work was to develop controlled release oral liquid losartan potassium. This employed a combination of in situ gelation and coating drug particles with pH-dependent polymer (Eudragit® L100). Solid dispersion (SD) prepared at 1:1, 1:1.5, and 1:2 drug : polymer ratios, respectively. Sodium alginate solution was loaded with either pure drug or SD, in presence and absence of 1% w/v chitosan. These systems were evaluated for the drug release using continuous pH variation study. Alginate formulation with pure drug underwent in situ gelation in the gastric conditions but lost the gelling strength in the intestinal phase with burst drug release. Loading the formulation with SD resulted in controlled drug release both in the gastric and intestinal phases. Increasing eudragit concentration in SD decreased the drug released with total release efficiency of 62.1%, 53.0%, and 41.7%. Incorporation of chitosan at reduced further drug release rate reaching 21% at the higher eudragit concentration. The study provided the formulator with a range of oral liquid formulations for controlled release of losartan potassium.
Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Becherán-Marón L, Peniche C, Argüelles-Monal W. Study of the interpolyelectrolyte reaction between chitosan and alginate: influence of alginate composition and chitosan molecular weight. Int J Biol Macromol, 2004; 34(1-2):127-33. https://doi.org/10.1016/j.ijbiomac.2004.03.010
Cetin M, Atila A, Kadioglu Y. Formulation and in vitro characterization of Eudragit® L100 and Eudragit® L100-PLGA nanoparticles containing diclofenac sodium. AAPS PharmSciTech, 2010; 11(3):1250-6. https://doi.org/10.1208/s12249-010-9489-6
El Maghraby GM, Elsisi AE, Elmeshad GA. Development of liquid oral sustained release formulations of nateglinide: in vitro and in vivo evaluation. J Drug Deliv Sci Technol, 2015; 29:70-7. https://doi.org/10.1016/j.jddst.2015.06.011
El Maghraby GM, Elzayat EM, Alanazi FK. Investigation of in situ gelling alginate formulations as a sustained release vehicle for co-precipitates of dextromethrophan and Eudragit S 100. Acta Pharm, 2014; 64(1):29-44. https://doi.org/10.2478/acph-2014-0002
El Maghraby GM, Elzayat EM, Alanazi FK. Development of modified in situ gelling oral liquid sustained release formulation of dextromethorphan and eudrgit S100. Drug Dev Ind Pharm, 2012; 38(8):971-8. https://doi.org/10.3109/03639045.2011.634811
Emami J, Varshosaz J, Ahmadi F. Preparation and evaluation of a liquid sustained-release drug delivery system for theophylline using spray-drying technique. Res Pharm Sci, 2008; 2(1):1-11.
Essa EA, Diwakat M. Enhancement of simvastatin dissolution via surface solid dispersion; effect of carriers and wetting agents. J Appl Pharm Sci, 2015; 5(1):054-3.
Essa E, Negm M, Zin Eldin E, El Maghraby G. Fast disintegrating tablets of amiodarone for intra-oral administration. J Appl Pharm Sci, 2017; 7(01):064-72. https://doi.org/10.7324/JAPS.2017.70109
Gollapudi R, Javvaji H, Tadikonda RR, Arpineni V. Formulation and evaluation of sustained release matrix tablets of Losartan potassium. Res J Pharm Biol Chem Sci, 2014; 3(2):526-34.
Itoh K, Kubo W, Fujiwara M, Watanabe H, Miyazaki S, Attwood D. The influence of gastric acidity and taste masking agent on in situ gelling pectin formulations for oral sustained delivery of acetaminophen. Biol Pharm Bull, 2006; 29(2):343-7. https://doi.org/10.1248/bpb.29.343
Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol, 1975; 27(1):48-9. https://doi.org/10.1111/j.2042-7158.1975.tb09378.x
Khattab WM, Gad S, El-Sayed MM, Ghorab MM. Simple controlled release delivery system for an anti-hypertensive drug via buccal route. Br J Pharm Res, 2014; 4(10):1174-95. https://doi.org/10.9734/BJPR/2014/9789
Kim KH, Frank MJ, Henderson NL. Application of differential scanning calorimetry to the study of solid drug dispersions. J Pharm Sci, 1985; 74(3):283-9. https://doi.org/10.1002/jps.2600740312
Kubo W, Miyazaki S, Attwood D. Oral sustained delivery of paracetamol from in situ-gelling gellan and sodium alginate formulations. Int J Pharm, 2003; 258(1-2):55-64. https://doi.org/10.1016/S0378-5173(03)00163-7
Lee BJ, Cui JH, Kim TW, Heo MY, Kim CK. Biphasic release characteristics of dual drug-loaded alginate beads. Arch Pharm Res, 1998; 21:645-50. https://doi.org/10.1007/BF02976751
Miyazaki S, Kubo W, Attwood D. Oral sustained delivery of theophylline using in-situ gelation of sodium alginate. J Control Release, 2000; 67(2-3):275-80. https://doi.org/10.1016/S0168-3659(00)00214-5
Murata Y, Miyamoto E, Kawashima S. Additive effect of chondroitin sulfate and chitosan on drug release from calcium-induced alginate gel beads. J Control Release, 1996; 38(2-3):101-8. https://doi.org/10.1016/0168-3659(95)00098-4
Niraj VK, Srivastava N, Singh T, Gupta U. Sustained and controlled drug delivery system-As a part of modified release dosage form. Int J Pharma Sci, 2013; 2(5):586-601.
Nirmal HB, Bakliwal SR, Pawar SP. In-situ gel: new trends in controlled and sustained drug delivery system. Int J PharmTech Res, 2010; 2(2):1398-408.
Ribeiro AJ, Silva C, Ferreira D, Veiga F. Chitosan-reinforced alginate microspheres obtained through the emulsification/internal gelation technique. Eur J Pharm Sci, 2005; 25(1):31-40. https://doi.org/10.1016/j.ejps.2005.01.016
Sarwar S, Hossain MS. Development and evaluation of sustained release losartan potassium matrix tablet using kollidon SR as release retardant. Brazilian J Pharm Sci, 2012; 48(4):621-8. https://doi.org/10.1590/S1984-82502012000400005
Shah KP, Chafetz L. Use of sparingly soluble salts to prepare oral sustained release suspensions. Int J Pharm, 1994; 109(3):271-81. https://doi.org/10.1016/0378-5173(94)90389-1
Sharma M, Sharma V, Panda AK, Majumdar DK. Development of enteric submicron particle formulation of papain for oral delivery. Int J Nanomed, 2011; 6:2097-111. https://doi.org/10.2147/IJN.S23985
Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet, 2005; 44(8):797-814. https://doi.org/10.2165/00003088-200544080-00003
Velmurufan S, Srinivas P. Formulation and in vitro evaluation of losartan potassium mucoadhesive tablets. Asian J Pharm Clin Res, 2013; 6(3):125-30.
Vohra DD, Pagi KS, Rajesh KS. Losartan potassium loaded sustained release matrix tablets: influence of various hydrophilic and hydrophobic polymers on drug release behaviour. J Pharm Bioallied Sci, 2012;4(5):S79-80. https://doi.org/10.4103/0975-7406.94147
Wang L, Khor E, Lim LY. Chitosan-alginate-CaCl(2) system for membrane coat application. J Pharm Sci, 2001; 90(8):1134-42. https://doi.org/10.1002/jps.1067